Cambridge Researchers Test AI-Designed Universal Vaccine
The recent breakthrough by the University of Cambridge and its spin-out, DIOSynVax (DVX) Ltd, marks more than just a successful clinical trial; it signals a fundamental shift in how humanity prepares for biological threats. The successful Phase 1 trial of the pEVAC-PS vaccine—an AI-designed, needle-free “universal” coronavirus vaccine—is a preview of a future where we … Read more